P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or...

por Thompson, G R, Soriano, A, Cornely, O A, Kullberg, B J, Kollef, M, Vazquez, J A, Das, A F, Locke, J B, Sandison, T, Pappas, P G
Publicado 2023

P22 Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomized, double-blinded, multicentre Phase 2 and Phase 3 trials of rezafungin in the treatment of...

por Soriano, A, Thompson, G R, Cornely, O A, Kullberg, B J, Kollef, M, Vazquez, J, Honore, P M, Bassetti, M, Pullman, J, Dignani, C, Das, A F, Sandison, T, Pappas, P G
Publicado 2023